Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Daniel Catenacci Profile picture
@DocCatenacci
Sep 27, 2019 • 9 tweets • 2 min read • Read on X
Scrolly
FIGHT-202 anti-FGFR2 pemigatinib for FGFR2 fusion cholangiocarcinoma. Very impressive Image
3-arm non-randomized phase 2 Image
Primary endpoint ORR in cohort A FGFR2 fusion cohort Image
Incidence of FGFR2 fusion: Image
35% ORR ImageImage
PFS Image
OS Image
Enough for accelerated conditional approval???
#ESMO2019

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Daniel Catenacci

Daniel Catenacci Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DocCatenacci

Daniel Catenacci Profile picture
Feb 10, 2021
#Tweetorial1️
✅Only ~40-60% of GEA pts receive 2L Rx in the USA, & the treatment landscape is fragmented.
📌 pubmed.ncbi.nlm.nih.gov/25792290/
📌pubmed.ncbi.nlm.nih.gov/31056940/
@TumorBoardTues #TumorBoardTuesday Image
#Tweetorial2
✅The Phase III 2L RAINBOW study of paclitaxel-Ram vs Paclitaxel had improved OS, serving as a benchmark SOC
📌thelancet.com/journals/lanon… ImageImage
#Tweetorial3
✅The Phase III 2L KN061 study showed detriment for pts with PDL1 CPS 0 treated w pembro vs paclitaxel (no Ram!), and terminated this group early.
(green = pembro, red = paclitaxel)
📌 thelancet.com/journals/lance…
📌 thelancet.com/journals/lance… Image
Read 17 tweets
Daniel Catenacci Profile picture
Feb 10, 2021
#TumorBoardTuesday
1/3 CASE: 35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA profile NO HER2 amp (TP53 mt MAF 9.3%).
How would u treat this pt now?
#TumorBoardTuesday
2/3 CASE:35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA PROFILE w/o HER2 amp (TP53 mt MAF 9.3%). PS0
How would u treat this pt now?
3/3: Here’s a f/u related POLL:
Currently my preferred line to use trastuzumab-deruxtecan is:
Read 7 tweets
Daniel Catenacci Profile picture
Sep 24, 2020
Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577
1st, thank you to all the pts who participated!
& 2nd, congrats to all the investigators involved!
It's fantastic to have +ve studies! Lets dive deep:
*Caution
I think the facts are accurate - please correct if not. (seeking the truth here)
My opinions are my opinions.
~15 min read (it's complicated)
No CME offered unfortunately 😒😉
Enjoy...
Background:
IO monotx effective in a subgroup of GEC pts in 1L+:
1. MSI-H
2. High PDL1 (cut-off at least CPS 10 22C3)
3. low tumor burden
4. PS0
5. Asian > Western pts
6. SCC > AC
7. GC > EGJ
Outside of above, most pts are better-served w chemo based on crossing #yinyang curves
Read 35 tweets
Daniel Catenacci Profile picture
Sep 3, 2020
Leading up to ESMO, would luv to hear predominant reason(s) why folks think CM649 is +ve but KN062 is -ve. Other ideas welcome! (Eg random chance that CM649 was +, or Kn062 missed a massive benefit by chance that now CM649 has uncovered!)
@marklewismd @Labrat3 @NataliyaUboha @OncLive @OncoAlert @rutikamehtaMD @DrR_DUNNE @rcarvalhoonco @RussellPetty19 @rachnatshroff @RenoHemonc @KlempnerSam @Thalcin @TargetedOnc @mgibson21212 @practiceupdate @benweinbergmd @BenWestphalen @SteveMaronMD @mdmanishshah @SyedMAhmedMDPhD
@pashtoonkasi @GIcancerDoc @DrBonillaOnc @CathyEngMD @koaeraser @ECActionNetwork @myESMO @eirinipec @FlavioRochaMD @FilippoPietran4 @LFerri123 @mgfakih @agrothey @GI_OncologyHub @DrGarridoOncoGI @HH_Oncodr @TedHong9 @ILSONDavid @YJanjigianMD @Marindoc @KlempnerSam @KoheiShitara
Read 4 tweets
Daniel Catenacci Profile picture
Aug 19, 2020
It will be important to look at the data closely, particularly by histology. Merck’s KEYTRUDA® (pembrolizumab) in Combination W Chemo Significantly Improved OS and PFS Compared W Chemo in 1L Metastatic Esophageal Cancer | Business Wire businesswire.com/news/home/2020…
We must recall that a ~500 pt study of the exact same regimen KN062 was recently statistically negative (HR0.85 p=0.046) in CPS>0 in adeno. Now the same regimen in KN590 N=749, in all-comers irrespective of PDL1 but including SCC, is +ve. What could be driving this difference?🤔
Let’s see the data: the make-up by histology (& PDL1!) & the benefit magnitude diffs (as might be expected) b/w them before we jump to conclusions on both CM577 and KN590, and also CM649. Let’s not make press releases drive the science! #esmo2020 is going to be a doozy for #GEA!!
Read 6 tweets
Daniel Catenacci Profile picture
Jul 10, 2020
So great that HER2+ GEA has many promising new tx’s! The next yrs will be important for us to study how to optimally sequence of all of them to best treat our pts!!
#margetuximab #tras #tucatinib #trasderux #zw25 etc...

#retifanlimab #pembro #nivo etc...

thelancet.com/journals/lanon… Image
In addition to the main text, be sure to check out pages 4-11 of the supplement. Lots of good stuff buried there. Most important to me are the biomarker subgroups analyses: “Targeted therapies for targeted populations!” Some long-term survival noted in the double-positive group. Image
Important observations to me:
1. All observed responses were IHC 3+ at 1L dx.
2. 79% of responses were PDL1 CPS>1 at 1L dx
3. 88% of responses were ctDNA HER2+ at time of enrollment prior to 2L tx on study.
4. ⬆️est response was amongst those with all 3 of those biomarkers+. ImageImageImage
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(